CLINICAL TRIALS PROFILE FOR TESAGLITAZAR
✉ Email this page to a colleague
Clinical Trials for Tesaglitazar
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT00214565 ↗ | GALLANT 6 Tesaglitazar vs. Pioglitazone | Terminated | AstraZeneca | Phase 3 | This is a 24-week randomized, double-blind, multi-center, active-controlled (pioglitazone) study of tesaglitazar (0.5 mg and 1 mg) in patients with type 2 diabetes, not adequately controlled on diet and lifestyle advice alone during the run-in period. The study comprises a 3-week enrollment period, 6 week placebo single blind run in period followed by a 24-week double blind treatment period and a 3-week follow-up period. |
| NCT00214591 ↗ | GALLANT 5 Tesaglitazar Versus Metformin | Terminated | AstraZeneca | Phase 3 | This is a 52-week randomized, double-blind, parallel-group, multi-center, active-controlled (metformin) study of tesaglitazar in patients with type 2 diabetes, not adequately controlled on diet and lifestyle advice alone during the run-in period. The study comprises a 6 week placebo single blind run in period followed by a 52-week a double blind treatment period and a 3-week follow-up period. Tesaglitazar and metformin will be titrated to optimal effect or highest tolerable dose during the first 12 weeks. |
| NCT00226330 ↗ | GALLEX 6: Study to Evaluate the Safety and Tolerability of Tesaglitazar in Patients With Type 2 Diabetes Mellitus | Terminated | AstraZeneca | Phase 3 | This is a parallel-group, multi-center, long-term extension study from the GALLANT 6 study to monitor the safety and tolerability of oral tesaglitazar compared with pioglitazone in patients with type 2 diabetes for up to 104 weeks of treatment. The total duration, including treatment and follow-up, is 107 weeks. |
| NCT00229684 ↗ | ARMOR (Analyzing Renal Mechanisms of Creatinine Excretion in Patients On tesaglitazaR) | Terminated | AstraZeneca | Phase 2 | This is a prospective 24-week, randomized, parallel-group, multi-center, active-controlled (pioglitazone 45 mg) open-label study designed to assess the effects of tesaglitazar 2 mg per day on components of renal excretion of creatinine in type 2 diabetics. The study comprises a 2-week enrollment period, followed by a 24-week double blind treatment period and an 8-week follow-up period |
| NCT00229710 ↗ | GALLEX 9: Safety and Tolerability of Oral Tesaglitazar When Added to Insulin Therapy in Patients With Type 2 Diabetes | Terminated | AstraZeneca | Phase 3 | This is a 140-week open-label, multi-center long-term extension study from GALLANT 9 to monitor the safety and tolerability of oral tesaglitazar 0.5 mg and insulin in patients with type 2 diabetes during up to 140 weeks of treatment. The total duration, including treatment and follow-up, is 143 weeks. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Tesaglitazar
Condition Name
Clinical Trial Locations for Tesaglitazar
Trials by Country
Clinical Trial Progress for Tesaglitazar
Clinical Trial Phase
Clinical Trial Sponsors for Tesaglitazar
Sponsor Name
